Peptide distribution platforms attract financing while testing regulatory durability

System reportedly raised $20 million to expand a clinician-mediated peptide prescribing and pharmacy-network model, with claimed third-party testing and planned API manufacturing. Demand signals remain difficult to validate, while sourcing, pharmacy oversight, testing independence, regulatory durability, and execution remain open questions.